Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets.
In the absence of effective vaccines to control herpesvirus infections, nucleosidic antiviral drugs have been the mainstay of clinical treatment since their development in the late 1970s. However, given the drawbacks of these drugs, including the increasing emergence of drug-resistant clinical isolates, new strategies for treating herpesvirus infections are warranted. A range of promising new drugs with novel molecular targets has been developed, but will they cure latent infections?
Coen
Donald M
DM
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachussets 02115, USA. don_coen@hms.harvard.edu
Schaffer
Priscilla A
PA
D000998:Antiviral Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D006564:Herpesviridae / Q000187:drug effects* / Q000472:pathogenicity; D006566:Herpesviridae Infections / Q000188:drug therapy*; D006801:Humans; D019384:Nucleic Acid Synthesis Inhibitors
D000998:Antiviral Agents; D019384:Nucleic Acid Synthesis Inhibitors